James DiRenzo
Papers
1
Total Citations
67
H-Index
1
About
James DiRenzo is a leading cancer biologist whose work centers on cell cycle regulation and targeted therapies for lung cancer. His research has fundamentally advanced our understanding of how cyclin-dependent kinases (Cdks) and their cyclin partners drive tumor growth, particularly through the cyclin E-Cdk-2 complex. In his landmark 2009 study, DiRenzo demonstrated that disrupting this complex in lung cancer cells does not merely halt proliferation but triggers a novel cell death mechanism he termed "anaphase catastrophe." This finding, cited over 67 times, revealed an unexpected vulnerability in lung cancers that overexpress cyclin E, offering a new therapeutic strategy distinct from conventional Cdk inhibitors. By identifying the precise consequences of targeting this axis, DiRenzo has provided a mechanistic rationale for developing more selective drugs that exploit mitotic failure. His work bridges fundamental cell cycle biology with translational oncology, making him a key figure in the quest for smarter, less toxic lung cancer treatments. For students and researchers, DiRenzo exemplifies how dissecting the molecular details of cell division can uncover powerful new avenues for therapy.
Research Focus
Key Achievements
Top Papers
- 1